OSR Holdings, Inc. 8-K

What Happened
OSR Holdings, Inc. (through its subsidiary Vaximm AG) announced a binding term sheet dated March 23, 2026 with BCM Europe AG that revises a prior agreement and establishes a new global exclusive license structure for VXM01. Under the revised arrangement OSR Holdings is a direct counterparty and will be the primary recipient of milestone and royalty payments; BCME will receive an exclusive, worldwide, sublicensable license to develop and commercialize VXM01 upon closing of a definitive license agreement.

Key Details

• Term Sheet dated March 23, 2026, supersedes the prior term sheet dated January 13, 2025.
• BCME is responsible for up to $815.0 million in milestone payments, payable directly to OSR Holdings.
• OSR Holdings will provide a development financing facility to Vaximm of up to $30.0 million.
• Execution of a definitive license agreement is subject to customary conditions, including due diligence, board approvals and receipt of an independent fairness opinion.

Why It Matters
This arrangement could create a significant potential revenue stream for OSR Holdings (milestones and future royalties) and makes OSR the direct counterparty for those payments rather than only its Vaximm subsidiary. However, the deal is not final—payments and license rights depend on execution of a definitive agreement and future development/commercial milestones. Investors should note the potential upside from large milestone obligations and the ongoing execution risk while the company completes due diligence and approvals.